On Monday, Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) was -4.37% drop from the session before settling in for the closing price of $0.21. A 52-week range for ADAP has been $0.20 – $1.55.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 193.37% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -56.09%. With a float of $226.52 million, this company’s outstanding shares have now reached $255.94 million.
In an organization with 506 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 96.95%, operating margin of -38.62%, and the pretax margin is -39.06%.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Adaptimmune Therapeutics Plc ADR stocks. The insider ownership of Adaptimmune Therapeutics Plc ADR is 11.49%, while institutional ownership is 37.39%. The most recent insider transaction that took place on Jan 17 ’25, was worth 3,243. In this transaction Chief Medical Officer of this company sold 5,584 shares at a rate of $0.58, taking the stock ownership to the 7,510 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Patient Supply Officer sold 5,584 for $0.58, making the entire transaction worth $3,243. This insider now owns 7,510 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -56.09% per share during the next fiscal year.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
You can see what Adaptimmune Therapeutics Plc ADR (ADAP) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.29, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.36 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Let’s dig in a bit further. During the last 5-days, its volume was 2.8 million. That was better than the volume of 1.55 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 1.41%. Additionally, its Average True Range was 0.04.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 0.00%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 189.45% in the past 14 days, which was higher than the 103.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4974, while its 200-day Moving Average is $0.8077. However, in the short run, Adaptimmune Therapeutics Plc ADR’s stock first resistance to watch stands at $0.2068. Second resistance stands at $0.2166. The third major resistance level sits at $0.2215. If the price goes on to break the first support level at $0.1921, it is likely to go to the next support level at $0.1872. The third support level lies at $0.1774 if the price breaches the second support level.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
There are 255,883K outstanding shares of the company, which has a market capitalization of 50.42 million. As of now, sales total 60,280 K while income totals -113,870 K. Its latest quarter income was 40,900 K while its last quarter net income were -17,620 K.
